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Summary Isolated limb perfusion with tumour necrosis factor alpha (TNF-a) and melphalan is well tolerated and highly effective in
irresectable sarcoma and melanoma. No data are available on isolated hepatic perfusion (IHP) with these drugs for irresectable hepatic
malignancies. This study was undertaken to assess the feasibility of such an approach by analysing hepatic and systemic toxicity of IHP with
TNF-a with and without melphalan in pigs. Ten healthy pigs underwent IHP. After vascular isolation of the liver, inflow catheters were placed
in the hepatic artery and portal vein, and an outflow catheter was placed in the inferior vena cava (IVC). An extracorporeal veno-venous
bypass was used to shunt blood from the lower body and intestines to the heart. The liver was perfused for 60 min with (1) 50 ,ug kg-' TNF-ca
(n = 5), (2) 50 9g kg-' TNF-a plus 1 mg kg-' melphalan (n = 3) or (3) no drugs (n = 2). The liver was washed with macrodex before restoring
vascular continuity. All but one pigs tolerated the procedure well. Stable perfusion was achieved in all animals with median perfusate TNF-a
levels of 5.1 ± 0.78 x 106 pg ml- (± s.e.m). Systemic leakage of TNF-a from the perfusate was consistently < 0.02%. Following IHP, a
transient elevation of systemic TNF-a levels was observed in groups 1 and 2 with a median peak level of 23 ± 3 x 103 pg ml-' at 10 min after
washout, which normalized within 6 h. No significant systemic toxicity was observed. Mild transient hepatotoxicity was seen to a similar extent
in all animals, including controls. IHP with TNF-a with(out) melphalan in pigs is technically feasible, results in minimal systemic drug exposure
and causes minor transient disturbances of liver biochemistry and histology.
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The liver is the commonest site of dissemination in patients with
colorectal cancer (Bengmark, 1969; Wagner, 1984; Strangl, 1994).
Five-year survival rates of up to 35% have been reported for
patients amenable for partial hepatic resection (Hughes, 1986;
Scheele, 1990; Van Ooyen, 1992; Sugihara, 1993; Que, 1994).
Unfortunately, the vast majority ofcolorectal metastases confined
to the liver are considered to be unresectable (Greenway, 1988;
Cady, 1991; Genari, 1992). In addition, systemic chemotherapy
has so far failed to provide satisfactory results in these cases
(Kemeny, 1983, 1987). Therefore, it is mandatory to develop
novel strategies to obtain tumour control in the liver.
The concept of locoregional administration of chemotherapy is
aimed at achieving high local concentrations while minimizing
systemic drug levels in an attempt to reduce dose-limiting side-
effects. This might enhance anti-tumour efficacy as steep
dose-response curves have been described for most chemothera-
peutic agents (Frei, 1980; Canellos, 1987). Several techniques
have been developed for regional therapy ofhepatic malignancies,
of which hepatic artery infusion (HAI) has become most widely
used (Sullivan, 1964; Pentecost, 1993; De Takats, 1994). Although
HAI has been shown to improve short-term tumour response rates
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over systemic chemotherapy, it only slightly affects survival,
while significant dose-limiting toxicity has been encountered
(Kemeny, 1987; Pentecost, 1993; De Takats, 1994; Chang, 1987).
Alternatively, isolated hepatic perfusion (IHP), including total
vascular isolation of the liver, has been reported to significantly
increase intrahepatic drug concentrations when compared with
HAI, while maintaining sufficiently low systemic drug levels
(Aigner, 1982; Skibba, 1983; De Brauw, 1988; Marinelli, 1991;
Radnell, 1990). However, large animal studies have revealed
systemic leakage of the perfused anti-tumour agent owing to
incomplete vascular isolation in up to 20% of animals (Sindelar,
1985; Van de Velde, 1986). Although incidental clinical reports on
IHP have confirmed its potential use in humans (Aigner, 1988;
Skibba, 1988; Hafstrom, 1994), it is clear that optimization of the
IHP methodology is needed. In addition, a drug(s) that would
provide optimal anti-tumour activity in the IHP setting is at
present unknown.
High-dose tumour necrosis factor alpha (TNF-a) has been
shown to be highly tumoricidal both in vitro and in vivo
(Alexander, 1991; Jiiattelai, 1991; Sidhu, 1993). Many phase I and
II studies have demonstrated that systemic administration ofTNF-
ax in man results in considerable dose-limiting toxicity at dose
levels at which no anti-tumour activity is observed (Asher, 1987;
Blick, 1987; Feinberg, 1988). On the other hand, isolated limb
perfusion with high-dose TNF-a in combination with the alky-
lating agent melphalan has recently been documented to be
extremely effective in patients with irresectable soft-tissue
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sarcomas and in patients with stage III melanoma (Eggermont,
1996a,b; Lienard, 1994). Although the exact mechanism of the
anti-tumour action by TNF-a is unknown, endothelial injury ofthe
tumour-associated vasculature has been suggested to play apivotal
role in inducing tumour necrosis (Watanabe, 1988; Renard, 1994;
Cid, 1994). Thus, TNF-a may be effective against any histological
tumour variant, provided that the tumour has a well-developed
vascular bed.
It is not known whether intrahepatic administration of TNF-a
via IHP is feasible with a satisfactory degree of safety. It is
possible that TNF-a might induce significant hepatotoxicity as
Kupffer cells are known to release various cytokines in response to
TNF-a exposure (Shirahama, 1988; Busam, 1990). The present
study in healthy pigs was performed to determine the effects of
IHP with TNF-ax, with and without melphalan, with emphasis on
hepatic and systemic toxicity. For this purpose, a modification of
previously reported IHP techniques was developed and tested.
MATERIALS AND METHODS
Isolated hepatic perfusion
Ten healthy pigs weighing 25-33 kg (median 30 kg) were used.
All animals received humane care in compliance with the guide-
lines on animal welfare of the Erasmus University, Rotterdam.
General anaesthesia was induced and maintained with pavulon
and fentanyl. Before surgery, all pigs received 0.1 ml kg-'
Depomycine, consisting of 200 000 IU ml-' of procaine penicillin
and 200 mg ml-' ofdihydrostreptomycin. In all animals, an arterial
line was introduced into the right carotid artery; a tunnelled
double-lumen central venous catheter and Swan-Ganz catheter
were placed in the right external and internal jugular veins respec-
tively. In addition, the left external jugular vein was dissected in
preparation for the veno-venous bypass shunt (see below). Via a
midline abdominal incision, the liver was mobilized by transecting
all ligaments, and the supra- and infrahepatic inferior vena cava
(IVC) were dissected and encircled. The hepatoduodenal ligament
was meticulosuly dissected preserving the common bile duct,
coeliac trunk, portal vein (PV) and hepatic artery (HA). Branches
of the-PV and the HA, particularly those arterial branches running
towards duodenum and stomach, were ligated as needed to obtain
complete vascular isolation of the liver. The right common iliac
vein was dissected free. After heparinization with 2 mg kg-i
heparin, a veno-venous bypass circuit (VVB) was established
using an inverted Y-shaped cannula to shunt mesenteric, renal and
lower extremity blood around the liver back to the heart. For this
purpose, a 20F cannula was introduced into the right common iliac
vein, passed into the infrarenal IVC, and the free end was
connected with one ofthe two lower limbs ofthe inverted Y. Next,
the left jugular vein was cannulated (20F) and connected to the
upper limb of the inverted Y. To complete the VVB, the distal PV
was clamped, cannulated (20F) and connected with the remaining
lower limb. Directly before opening the VVB, a clamp was placed
on the infrahepatic suprarenal IVC, proximal from the cannula tip.
The VVB flow was aided by a centrifugal pump (Medtronic,
Biomedics, USA) in a manner identical to the technique currently
used during liver transplantation procedures (Starzl, 1990). The
liver perfusion circuit was established by introducing a 20F
cannula into the hepatic side of the PV. A 24F venous outflow
catheter was placed into the suprarenal, infrahepatic IVC via a
longitudinal phlebotomy (including the pericaval hepatic tissue)
and passed into the retrohepatic IVC. These two catheters were
connected to the extracorporeal circuit (see below) and, after
clamping of the suprahepatic IVC and the hepatic artery (HA),
portal liver perfusion was allowed immediately in an attempt to
minimize anoxic liver damage (first anoxia time). Finally, the HA
was cannulated with an 8F catheter, which was subsequently
connected, thus completing the isolated liverperfusion circuit. The
extracorporeal perfusion circuit consisted of a double head roller
pump, VPCML membrane oxygenator with integrated heat
exchanger and reservoir, and arterial blood filters, analogous to the
extracorporeal circuit used during cardiopulmonary bypass proce-
dures. The circuit was primed with 500 ml of colloid solution
(Haemacel) and 500 ml of porcine blood. In addition, sodium
hydrocarbonate 8.4% was added to the priming infusion (15-
20 ml). Portal and arterial flow rates and pressures, together with
the oxygen saturation levels in the perfusate, were recorded as
indicated by the heart-lung machine. The flow rates in the VVB
shunt were also documented. In addition, the portal flow rates
were measured before and immediately after IHP using an 8-mm
35B548 flow probe (Transonic Systems, Ithaca, NY, USA)
connected to a Transonic T206X flowmeter (AB Medical,
Roermond, The Netherlands). Once stable perfusion was estab-
lished, as judged by the reservoir level, absence of systemic
leakage from the IHP circuit was confirmed by injection of 1 cm3
of a 1:10 dilution of fluorescein into the arterial circuit, followed
by illumination with a UV (Woods) lamp. The perfusate was
heated to 40°C using a cooler/heater device and was kept at
2 39°C throughout the drug perfusion period. After 60 min of
perfusion the liver was washed with Macrodex (> 1500 ml) until
the fluid from the hepatic veins was clear. In order to restore phys-
iological hepatic perfusion, the HA was decannulated and repaired
with Prolene 7-0, whereafter the HA and VCI clamps (second
anoxia time) were released. Next, the ICV and PV were decannu-
lated and sutured (Prolene 5-0). The VVB was further dismantled
by decannulating and ligating the left internal jugular vein and
right common iliac vein respectively. Heparin was reversed by
injection ofprotamine. Pigs were sacrificed 4-6 weeks after IHP.
Table 1 Technical dataa
Control TNF TNF/melphalan
(n=2) (n=5) (n=3)
Anoxic period (min)
First 0±0 1±2 0±0
Second 6±1.4 13±3 13±3
Flow rate VVB (ml min-') 1125 + 176 1053± 50 1117± 29
Perfusion pressure (mmHg)
HA 125±35 110±46 178±54
PV 33+4 38±6 43±6
Perfusion flow rate (ml min-')
HA 225 ± 14 237 121 178+21
PV 470 ± 42 350 71 407+55
Perfusate oxygen saturation (%) 77 ± 2 73±5 72 ± 1
aTechnical perfusion data as indicated by pump and heart-lung machine.
Data are presented as means ± s.e.m. First anoxic period is defined as time
between clamping and portal perfusion; second anoxic period as time
between initiation of wash out and arterial recirculation.
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Figure 1 Course of liver biochemistry parameters as a function of time (days) following hyperthermic isolated hepatic perfusion (IHP) in pigs on day 0.
Error bars have been omitted for reasons of clarity. Standard deviations never exceeded 10% of the mean values depicted. -_-, Control; +, TNF;
TNF + melphalan
Drugs
Recombinant human tumour necrosis factor alpha (rhTNF-a)
(0.2 mg per ampoule) was a kind gift from Boehringer Ingelheim,
Germany. The cytostatic drug melphalan (Alkeran) was obtained
as a sterile powder (100 mg) that was dissolved aseptically using
solvent and diluent by Burroughs Wellcome (London, UK).
Treatment schedule
In five pigs, a 60-min hyperthermic IHP was performed with
rhTNF-a (50 gg kg-') alone, while three pigs were treated by IHP
with rhTNF-a (50 gg kg-') plus melphalan (1 mg kg-'). TNF was
administered as a bolus in the arterial line of the perfusion circuit;
melphalan was given directly following the rhTNF bolus. In two
control pigs, no drugs were added (sham group).
Sampling schedule
Perfusate was sampled at t = 0 (i.e. upon drug administration), 15,
30, 45 and 60 min. Systemic blood samples were collected the day
before IHP, during IHP at t = 0, 15, 30, 45 and 60 min and after
perfusion at t = 1, 10, 30, 60, 120 and 480 min, days 1, 3, and 7 and
weekly thereafter. Blood samples were centrifuged at 5000 r.p.m.
for 5 min. Supernatants were stored at-70°C until analysis. Biliary
samples (approximately 5-10 ml) were taken by direct puncture of
the gall bladder before IHP, immediately after IHP and upon
closure ofthe abdomen.
TNF-a assay
TNF-a was measured by a sandwich-type ELISA using two
monoclonal antibodies (Department of Immune Reagents, Central
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Laboratory ofBlood Transfusion, Amsterdam, Netherlands) raised
against rhTNF-a (courtesy of Dr A Creasey, Chiron, Emeryville,
CA, USA). One MAb (MAb CLB-TNFcx-7) was used for coating
at a concentration of 2 jg ml-'; the second MAb (MAb CLB-
TNFax-5) was biotinylated and used in combination with strepta-
vidin poly-horseradish peroxidase conjugate to detect bound
TNF-cc. Stimulated human mononuclear cell supernatant was used
as a standard for comparison with purified rhTNF-a. Results were
expressed as pg ml-' by reference to this standard.
Histology
Multiple liver biopsies were taken before and directly after IHP
and upon sacrifice at 4-6 weeks post-operatively. The tissue
samples were fixed in formaldehyde and embedded in paraffin.
Five-micrometre sections were stained with haematoxylin and
eosin (HE). In addition, samples were taken from all animals in
preparation for electronmicroscopy (EM).
Statistics
Comparisons within and between groups were made by analysis of
variance for repeated measurements (ANOVA) or by the t-test
where appropriate. Correlations between maximum or minimum
levels ofparameters were calculated as Spearmann's rank correla-
tions. The significance level was taken as aprobability (two-sided)
of< 0.05.
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RESULTS
The duration ofthe operation ranged from 4 to 7 h (median 6 h). In
all animals, a stable perfusion was achieved with no apparent
leakage as demonstrated by the fluorescein dye injection. Further
technical details are summarized in Table 1. As indicated by the
oxygen saturation levels in the perfusate, adequate tissue perfusion
was attained in all cases. In addition, the measured flow rates in
the PV did not differ significantly before and after IHP in all
groups. Median blood loss was 500 ml (range 300-1500 ml),
including blood lost in the perfusion circuit. All pigs survived the
operation. One animal in the TNF-alone group died on the first
post-operative day. At necropsy, clear, serosanguinous fluid was
observed in the abdomen without evidence of portal hyper-
tension/thrombosis or surgical haemorrhage. One pig in the
TNF/melphalan group underwent relaparotomy for hernia cicatri-
calis 2 weeks after IHP; onepig in the TNF-alone group developed
pneumonia with elevated leucocyte counts 4 weeks after perfu-
sion. At the time of necropsy, all remaining animals were in good
general condition, with weights ranging from 30 to 40 kg. In fact,
4 weeks after IHP, all surviving animals had gained weight.
Weight gains did not differ significantly between groups.
Macroscopic post-mortem examination did not reveal any intra-
abdominal or intrathoracic abnormalities.
In all animals, IHP resulted in significant elevations of ASAT,
ALAT, LDH and alkaline phosphatase levels, with peak values
occurring on day 1 post-operatively (Figure 1). Transaminase
levels returned to normal within the first 7-10 post-operative days,
while alkaline phosphatase and LDH remained slightly elevated
throughout the observation period. Total bilirubin values remained
within the normal range (Figure 1), as did the serum values of
urea, y-GT and creatinin (data not shown). There were no signifi-
cant differences in peak values or kinetics between the three
D-1 0 15 30 45 60 +1 10 30 60 120 480 D1 DW D7
Pre-IHP Minutes Days
Figure 2 Perfusate (A) and systemic (B) TNF-a levels (pg ml-1) as a function
of time before, during and after IHP in pigs. -U-, TNF; *, TNF/melphalan;
-W, control
groups. In all groups, serum albumin levels decreased to a nadir of
approximately 22 g 1-' on the first post-operative day and returned
to normal values within the next 7-14 days, (Figure 1).
Haemoglobin and haematocrit remained normal throughout the
follow-up period (data not shown). In contrast, platelet counts
decreased slightly, but not significantly, during the first post-
operative day and normalized within 3-7 days.
TNF-a levels in the perfusate of the pigs in the TNF-alone
group increased to a median of 5.0 x 106 pg ml' (range 4.9-
6.3 x 106); compared with 5.2 x 106pg ml-' (5.1-6.6 pg ml') in the
TNF/melphalan group. These perfusate TNF-o levels remained
virtually stable throughout the 1-h perfusion period. Perfusate
TNF-a levels in the control group remained normal (i.e.
< 5 pg ml-') during IHP (Figure 2). At t = 0 (i.e. at the beginning of
the perfusion), all animals displayed normal systemic TNF-x
levels. During IHP, systemic TNF-a levels in the control group
increased to a median of 12 pg ml' (8.9-15 pg ml-') at t = 60 min,
compared with 76 pg ml-' (41-120 pg ml') in the TNF-alone
group and 139 pg ml' (34-197 pg ml') in the TNF/melphalan
group. These figures indicate that, in both experimental groups,
cumulative systemic leakage ofTNF-a from the perfusate was less
than 0.02% during the 60-min perfusion. However, following
washout and decannulation at the end of the perfusion, systemic
TNF-(x levels increased significantly in the TNF-alone group
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and the TNF/melphalan group, with median peak levels of
3.2 x 103 pg ml-l and 17 x 103 pg ml-' respectively (Figure 2).
These peak levels occurred between 1 and 30 min (median 10 min)
after washout and returned to normal within 480 min after IHP.
Again, there were no significant differences between the two
experimental groups. Systemic post-perfusion TNF-ox levels in the
control animals rose slightly, but not significantly, to a maximum
value of26 pg ml-' at t = 60 min after washout. None ofthe biliary
samples evaluated contained detectable levels ofTNF-at.
Compared with pre-perfusion histology, microscopic examina-
tion of HE-stained sections taken directly after perfusion showed
mild sinusoidal dilatation as well as septal oedema with sporadic
intraseptal polymorphonuclear cell (PMN) infiltration. These find-
ings were documented in all animals, including the controls. There
was no apparent hepatocellular damage or parenchymal necrosis.
At 4-6 weeks after IHP, all microscopical sections revealed
normal pig liver histology (on both HE and EM), with the excep-
tion of sporadic PMN infiltrates in the liver parenchyma. The
septal oedema and sporadic septal infiltration had disappeared in
all specimens investigated. Again, these findings were similar in
all three groups.
DISCUSSION
The data presented here demonstrate that, in the pig model used,
hyperthermic isolated perfusion of the liver via both the HA and
the PV is technically feasible and appears to be a safe procedure.
Nevertheless, the current IHP technique still involves a large
operation, as illustrated by the median duration of 6 h and the one
post-operative death. Additional modifications, including the use
of balloon catheters, are therefore being studied at present.
Temporary exposure of normal porcine liver parenchyma to high-
dose rhTNF-ax, with and without melphalan, in combination with
hyperthermia is well tolerated and results in mild, transient
hepatotoxicity. This was illustrated by early elevation of liver
enzyme levels, followed by a spontaneous return to normal levels.
On histological examination, immediate post-perfusion changes
included sinusoidal dilatation and mild septal oedema, without any
signs of hepatocellular injury. Sections taken 4-6 weeks after IHP
revealed sporadic, periportal infiltrates in otherwise normal
hepatic parenchyma. Most biochemical and histological alterations
following IHP were similar in both control and experimental
animals. This suggests that the mild hepatotoxic phenomena
observed were primarily caused by the IHP procedure itself and
that the addition of the drugs used, in particular rhTNF-a, does not
lead to additional hepatotoxicity. These findings are in agreement
with those reported on IHP with hyperthermia and/or standard
chemotherapeutics (Skibba, 1983, 1988; Sindelar, 1985; Van de
Velde, 1986; Aigner, 1988; Hafstrom 1994).
Complete vascular isolation ofthe liver during IHP is essential to
avoid systemic exposure to high doses of antitumoral agents.
Previous studies on IHP in large animals, using somewhat different
methodologies, have mentioned technical difficulties resulting in
incomplete vascular isolation and systemic leakage ofdrugs. Van de
Velde et al (1986) reported leakage in 3 out of 15 pigs treated with
IHP, whereas Sindelar et al (1985) encountered incomplete vascular
isolation in 2 out of 10 pigs, resulting in severe systemic drug-asso-
ciated toxicity and death. In these studies, either a passive external
or an internal venous shunt was employed to drain distal portal and
lower body blood. In view of their findings, we modified the IHP
technique in an attempt to minimize leakage. This modification
involved the introduction ofa separate, second active circuit which
consisted of a pump-aided, extracorporeal veno-venous bypass
shunt (VVB) connecting cannulas in the distal PV and infrarenal
IVC with the external jugular vein. Besides simplifying the hepatic
perfusion circuit in this manner (as opposed to internal venous
shunts), the VVB has the additional advantage of more efficiently
shunting blood from the lower body, kidneys and intestines to the
heart. As a result, the cardiac venous return increases, thereby
augmenting haemodynamic stability throughout the procedure. In
fact, we did not observe any haemodynamic instability during our
experiments in pigs, generally considered to be haemodynamically
sensitive. Moreover, we have been able to detect that there was no
significant leakage from the liver perfusion circuit to the systemic
circulation. This was achieved using either of two qualitative
methods, i.e. observing fluorescent dye distribution or monitoring
perfusate reservoir levels. This was confirmed in a quantitative
manner by analysing, during the vascular isolation period, systemic
levels of TNF-ax, which remained approximately four orders of
magnitude lower than perfusate levels. In addition, all pigs survived
the procedure and no animal demonstrated any of the known
systemic side-effects of rhTNF-a in pigs during and after IHP
(Leighton, 1991; Truog, 1992).
However, following IHP and washout, an additional rise in
systemic TNF-ax levels was seen upon restoration of vascular
continuity. Although well below toxic concentrations of rhTNF in
the pig, this phenomenon still has to be accounted for. It is possible
that the washout procedure was not sufficiently effective in
removing all remaining TNF-a from the perfusate. This may be
particularly true in the non-tumour-bearing pig liver, in which
virtually no TNF-uptake was observed during IHP, as judged by
perfusate TNF-ax levels (Figure 2).
There is no consensus on the route of infusion (HA vs PV vs
both). Normal hepatic parenchyma receives most of its blood
supply from branches of the PV and to a much lesser extent from
the HA. In contrast, the blood supply of hepatic metastases is
reported to rely almost entirely on the HA (Strohmeyer, 1986).
Consequently, most regional approaches have been made using the
HA. More recently, however, attention has been drawn to the PV
as very small liver tumours (< 5 mm), as well as the outer rim of
larger hepatic metastases, are fed mainly by portal branches
(Archer, 1989). In addition, most colorectal tumours are drained
via the PV, suggesting that spreading tumour cells will first prolif-
erate in the portal system. Thus, by using the HA as well as the PV,
drugs will reach both established and newly formed (micro) metas-
tases. Taking this into consideration, we performed IHP via both
the HA as well as the PV. However, as most normal hepatic
parenchyme tissue is supplied primarily by the PV, it could be
speculated that infusion via the PV might induce significant
hepatotoxicity. Indeed, Boddie et al (1979) performed IHP solely
via the PV and demonstrated significant hepatic damage. In accor-
dance with most other reports on IHP, we have not been able to
confirm these findings (Skibba, 1983, 1988; Sindelar, 1985; Van
de Velde, 1986; Aigner, 1988; Hafstrom, 1994).
At present, it is unknown which drug, or combination of drugs,
would provide antitumoral efficacy in the IHP setting. TNF-x with
and without melphalan was selected for this study based on its clin-
ical success (100% limb salvage and a 90% overall response) in
isolated limb perfusions for irresectable melanoma and sarcoma
(Eggermont, 1994; Lienard, 1994). As at least part of the anti-
tumour effect of TNF-ax relies on the destruction of the tumour-
associated vessels, irrespective of tumour histology (Watanabe,
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1988; Renard, 1994; Cid, 1994), we reasoned that this combination
might well be effective against colorectal hepatic metastases.
Indeed, Van der Schelling et al (1992) have recently shown that
intratumoral administration of rhTNF-ax, under ultrasonographic
guidance, was able to stabilize disease in eight patients with hepatic
metastases at the cost of minimal systemic symptoms. As demon-
strated by Mavligit et al (1992), HA infusion ofrhTNF-ca permits a
more than sixfold dose increase ofthe maximum tolerated systemic
(i.v.) dose before adverse systemic side-effects are noted. In this
setting, TNF-a was found to induce tumour regression in approxi-
mately 30% ofpatients with irresectable colorectal liver metastases
(Mavligt, 1992). Because of the synergy between melphalan and
TNF-a, as demonstrated in earlier reports (Eggermont, 1996a,b;
Lienard, 1994), melphalan was chosen over 5-FU, the drug most
frequently used in conventional regimens against colorectal (liver)
metastases. For reasons of comprehensiveness, we also performed
IHP with TNF-x and 5-FU in two pigs. No mortality was encoun-
tered, and (hepatic) response patterns were identical to the ones
described above (data not shown).
On the other hand, Kahky et al (1990) have shown that intra-
portal administration of 100 ig kg-' day-' rhTNF-a results in
100% mortality in rats. Histological examination in their study
revealed mild passive congestion of the liver combined with
severe pulmonary oedema. As systemic administration ofthe same
dose ofrhTNF-a did not result in any deaths, it is unlikely that the
high mortality after intraportal injection was caused solely by
TNF-x (Kahky, 1990). TNF-a has been documented to induce the
production ofvarious cytokines (including IL-1, IL-6 and TNF-a)
by macrophages (i.e. Kupffer cells) (Shirahama, 1988; Busam,
1990). As the vast majority ofhepatic Kupffer cells are situated in
the (peri) portal area, such a secondary cytokine release might
explain the observed mortality. As far as we can judge, IHP with
rhTNF-a and melphalan in the healthy pig does not lead to such
dramatic cytokine-related side-effects.
In conclusion, hyperthermic IHP with rhTNF-a and melphalan
in pigs is technically feasible, resulting in minimal systemic
leakage of drugs and mild, transient hepatotoxicity. The addition
ofrhTNF-a and melphalan in the perfusate does not lead to addi-
tional hepatotoxic side-effects. As pig liver physiology is similar
to humans, IHP with rhTNF-a and melphalan should be consid-
ered for phase I evaluation in patients with irresectable hepatic
malignancy.
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